()
 
 

Overview

NovaBay is focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and community environments. Many of these infections have become increasingly difficult to treat because of the rapid increase in infectious microbes that have become resistant to current drugs. Our in vitro and in vivo tests have demonstrated that our compounds kill a wide range of bacteria, viruses and other infection causing microbes, including those that are resistant to multiple antibiotics. We are developing hospital indications ourselves and have partnered certain other indications with Alcon, the world's leading eye care company, and with Kinetic Concepts, Inc., (KCI), the leading company in advanced woundcare technology.


Contact Information

5980 Horton Street
Suite 550
Emeryville, CA 94608

tel: 510-899-8800
fax: 510-329-2032
http://www.novabaypharma.com

,  



Investor Relations



tel:
fax:
e-mail: info@novabaypharama.com




Stock

Exchange: TSX
Industry: Industrial
Market Cap: $79.6M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.